Evidence map›Paper›PMID 40536581›Full record

ArticleDiscover oncology2025

Prognostic related signature predicts the benefits of immunotherapy for kidney renal clear cell carcinoma.

Feng Xiong, Bowen Wang, Haoxun Zhang, Guoling Zhang, Boju Tao, Yiwen Liu, Chunyang Wang

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Feng XiongDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China.
Bowen WangDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China.
Haoxun ZhangDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China.
Guoling ZhangDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China.
Boju TaoDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China.
Yiwen LiuDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China.
Chunyang WangDepartment of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Youzheng Street #23, Harbin, China. 15504627313@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) stands as the pivotal pathological subtype of renal cell carcinoma. However, there exists a dearth of pertinent biological targets crucial for advancing the clinical application of ccRCC. In our investigation, we employed the weighted gene co-expression network analysis (WGCNA) to discern 13 distinct gene co-expression modules, with the yellow module exhibiting a pronounced association with tumorigenesis. Concurrently, we scrutinized 6147 differentially expressed genes through rigorous differential expression analysis. Through an intersecting approach with the genes within the yellow module, we pinpointed 265 cancer-related genes displaying notable differential expression. Subsequent Cox-regression analysis unveiled that among the 265 genes, four were notably linked to ccRCC prognosis. Furthermore, we executed single-sample gene set enrichment analysis (ssGSEA) on the signature comprising these four genes, subsequently deriving normalized enrichment scores (NESs). This investigation substantiated that the said signature bears significant implications for prognosis, holding the potential to forecast the efficacy of immunotherapy.

Indexed as

ImmunotherapyKidney renal clear cell carcinomaSensitivitySignatureWeighted gene co-expression network analysis

Identifiers

PMID40536581
PMCPMC12179015

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.